Cash and Teddy Bears: Recruitment Tactics Spark Outrage
Moderna is facing a major scandal in the United Kingdom. The pharmaceutical giant could soon be suspended from the Association of the British Pharmaceutical Industry (ABPI). This follows a damning investigation by the Prescription Medicines Code of Practice Authority (PMCPA).
At the center of the controversy are Moderna’s recruitment methods during its NextCOVE COVID-19 vaccine trials. According to PMCPA findings, Moderna offered £1,500 payments and teddy bears to children and their parents. These actions directly violated UK regulations banning financial inducements for trial participation.
Children aged 12 and older were targeted. Many experts see this as a serious ethical breach, especially since children were considered low-risk for severe COVID-19. Public backlash has been swift and fierce.
Evidence of Delay and Deception
Moderna claims it acted quickly once it became aware of the payments in January 2024. However, campaign group UsForThem uncovered evidence suggesting otherwise. Senior executives were reportedly informed about the unethical inducements as early as August 2023.
The delay in corrective action has led to accusations of a serious breach of trust. Critics argue that Moderna prioritized fast recruitment over maintaining ethical standards. Trust, they say, should never be sacrificed for speed, even during a pandemic.
Misleading Regulators and Hidden Industry Ties
The problems do not end with cash payments and teddy bears. The PMCPA also found that Moderna misled regulators about when it addressed the controversy. The company claimed immediate action, but evidence suggested months of inaction.
Additionally, Moderna broke transparency rules. A senior employee co-wrote promotional articles—including one with former UK vaccines minister Nadhim Zahawi—without disclosing their affiliation with the company. ABPI codes require companies to clearly state industry ties in all public communications. Moderna failed to do so.
These breaches add to a troubling pattern. In 2022, Moderna was penalized for using off-label data to promote its Spikevax vaccine. Confidence in the company’s compliance practices has steadily eroded.
Fines Criticized as Insufficient
The PMCPA fined Moderna around £58,000 for its latest violations. The breakdown includes £44,000 for the teddy bear inducements and £14,000 for the cash offers.
However, many politicians and advocacy groups have slammed the penalties as too small. Moderna’s revenue in 2023 reached nearly £7 billion, making the fine seem insignificant.
UK Member of Parliament Esther McVey called the fines “a slap on the wrist.” Molly Kingsley, co-founder of UsForThem, described the penalties as “laughably small.” Both argue that such fines fail to discourage large pharmaceutical companies from unethical behavior.
A Pattern of Misconduct
Moderna’s reputation has been under pressure for some time. The NextCOVE trial scandal marks its sixth breach of ABPI codes in recent months. Past violations include misleading promotional claims and improper advertising practices.
The PMCPA’s latest move—a full audit of Moderna’s governance and compliance systems—signals growing alarm. If the audit uncovers persistent issues, Moderna could be expelled from the ABPI.
Expulsion would be rare. It has happened only nine times in the last 40 years. If suspended, Moderna would lose access to industry events and face severe credibility damage in the UK market.
Industry-Wide Implications
The scandal extends beyond Moderna alone. It highlights the challenge of balancing rapid innovation with ethical responsibility, especially during global health emergencies.
The COVID-19 pandemic demanded speed. Yet, as critics point out, speed should not justify shortcuts. Ethical standards must remain a top priority.
Public trust in vaccines remains fragile in many communities. Incidents like this risk undermining that trust further. Stronger oversight and heavier penalties may be needed to hold pharmaceutical giants accountable.
As Molly Kingsley noted, companies must not be allowed to treat fines as “the cost of doing business.” Regulators are now under pressure to reform their penalty structures to match corporate revenues and the seriousness of breaches.
Looking Ahead: A Test for Moderna
Moderna faces a critical moment. The company must overhaul its compliance systems if it hopes to avoid suspension. Transparency, ethical recruitment, and clear communication must become central to its operations.
Rebuilding trust will not be easy. Paying small fines will not be enough. True reform will require a deep, genuine commitment to ethical practices at every level.
Meanwhile, the broader pharmaceutical industry is watching closely. Moderna’s case may set a new standard for how regulatory bodies respond to misconduct. In today’s skeptical world, accountability is not optional—it is essential.
About the Author
